Effect of Ellagic Ácid on the Components of Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Metabolic syndrome (MS) is a group of important cardiovascular risk factors: abdominal obesity, dyslipidemia, hyperglycemia, and high blood pressure. Treatment requires the introduction of pharmacological management that includes different medications for each component. Ellagic acid (EA) is a polyphenol that has shown health benefits in multiple experimental studies. AE is consumed by patients without a prescription; considering there aren't studies that demonstrate it's effectiveness on MS, it is important to evaluate the possible effects of AE on this pathology. METHODOLOGY: Current study is a double-blind, placebo-controlled clinical trial. The aim of this study is evaluating the effect of AE on the components of metabolic syndrome, insulin sensitivity, and insulin secretion.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Guadalajara
• Collaborator: National Council of Science and Technology, Mexico
• Treatments: Insulin; Insulin, Globin Zinc; Magnesium Oxide

Criteria

Inclusion Criteria:

• Metabolic Syndrome diagnosis based on IDF criteria

• Acceptance and signing of Informed Consent

Exclusion Criteria:

• Knew kidney, liver, heart or thyroid disease

• Systolic blood pressure ≥140 mmHg

• Diastolic blood pressure ≥90 mmHg

• Fast blood glucose ≥126 mg/dL

• TG ≥400 mg/dL

• C-LDL > 190 mg/dL

• BMI: ≥35 kg/m2

• Pregnancy or lactation period

• Knew pomegranate allergy

• Habitual warfarin, tolbutamide or carbamazepin consumption

• Effect on any component of metabolic syndrome drugs or suplements regular intake